Role of monocytes in the pathogenesis of antiphospholipid syndrome and potential therapeutic targets (Review).

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized primarily by arterial and/or venous thrombosis, obstetric complications and persistent positivity for antiphospholipid antibodies (aPLs). It has been proposed that the pathogenesis of APS is closely associated with vascular endothelial cell activation, complement activation and platelet activation. Notably, APS may be key to understanding the relationship between innate immune cells, and thrombosis and obstetric complications.

Analysis of related deaths in patients with systemic sclerosis combined with renal failure in the United States from 1999 to 2020.

To describe the number of deaths related to systemic sclerosis (SSc) having renal failure, the changing trend in ASMR, and causes of death using a multi-cause method. Annual death toll and ASMR data from 1999 to 2020 were obtained from the death database of the US CDC. All death certificates in the M34 (SSc) and N17-19 (renal failure) categories of the ICD-10 were selected as potential or related causes of death.

Mortality associated with systemic lupus erythematosus combined with heart failure in the United States (1999-2020): A multiple-cause-of-death study.

This study analyzes the number of deaths related to systemic lupus erythematosus (SLE) combined with heart failure (HF) in the United States from 1999 to 2020, as well as the changing trend and causes of death of age-standardized mortality rate (ASMR). The annual number of deaths and ASMR with M32 (SLE) and I50 (HF) as the causes of death from 1999 to 2020 were extracted from the mortality database of the US CDC. Referring to the ICD-10 classification standard, the epidemiology and related data were described, and the number of deaths and the trend of ASMR were analyzed.

Vitamin D affects antiphospholipid syndrome by regulating T cells (Review).

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by arterial and/or venous thrombosis, pathological pregnancies and persistent antiphospholipid antibodies. The occurrence and development of APS are complex and associated with immune disorders, with its prognosis remaining uncertain. Owing to its pathogenesis, anticoagulation therapy is the primary treatment for patients with APS.

Potential of resveratrol in the treatment of systemic lupus erythematosus (Review).

Systemic lupus erythematosus (SLE) is a multi‑system chronic autoimmune disease with a complex occurrence and development process, associated with immune disorders, uncertain prognosis, and treatment modalities which vary by patient and disease activity. At present, the clinical treatment of SLE mainly focuses on hormones and immunosuppressants. In recent years, the research on new treatment strategies for SLE has been booming, and strong preclinical results and clinical research have promoted the development of numerous drugs (such as rituximab and orencia), but numerous of these drugs have failed to achieve effectiveness in clinical trials, and there are some adverse reactions.

Preliminary nomogram model for predicting irreversible organ damage of patients with systemic sclerosis.

Objective: To investigate predictive factors for irreversible organ damage in systemic sclerosis (SSc) and establish a nomogram model.

Methods: This retrospective study included patients with SSc who were treated at our hospital between March 2013 and March 2023. Irreversible organ damage included heart failure, respiratory failure, renal failure, and gangrene of the hands and feet.

Clinical characteristics of systemic sclerosis patients with occupational silicosis.

To explore the clinical characteristics of systemic sclerosis complicated with silicosis. The systemic sclerosis patients treated in the Guangxi Workers' Hospital and the People's Hospital of Guangxi Zhuang Autonomous Region from January 2000 to December 2020 were divided into the systemic sclerosis with silicosis group and the systemic sclerosis without silicosis group. Survival analysis was performed using Kaplan-Meier estimates the Cox proportional hazards model.

Alteration of Serum 25(OH) Vitamin D, Vitamin D Binding Protein, and C-reactive Protein Levels in Acute Leukemia Patients.

Background: Acute leukemia is a common hematologic malignancy with poorly differentiated leukocytes. Alteration of circulating vitamin D (VD) and its carrier vitamin D binding protein (VDBP) have been reported in certain types of cancers and may play a role in the course of the disease. Understanding of the status of serum VD and VDBP, as well as the acute phase protein C-reactive protein (CRP) levels in pre- and post-treatment of acute leukemia patients, may be helpful in the management of acute leukemia.

[Technetium 99Tc methylenediphosphonate inhibits osteoclast formation from PBMCs in patients with rheumatoid arthritis].

Objective: To observe the influence of technetium 99Tc methylenediphosphonate (99Tc-MDP) on osteoclastogenesis induced by receptor activator of NF-kappaB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF) in peripheral blood mononuclear cells in patients with rheumatoid arthritis, and to study the mechanism of 99Tc-MDP in osteoclast differentiation.

Methods: The monocytes/macrophages were isolated from peripheral blood in patients with rheumatoid arthritis, incubated in RPMI-1640 with receptor activator of NF-kappaB ligand (RANKL, 25 microg/L), macrophage-colony stimulating factor (M-CSF, 25 microg/L) and different concentrations of 99Tc-MDP (5, 10, 20 and 50 mg/L) for 4, 12, and 20 days. Tartrate resistant acid phosphatase staining was used to observe the formation of osteoclasts.